Contact A Lawyer
Near You

Contact us today for a complimentary consultation with a qualified attorney near you.

Pfizer voluntarily withdraws Bextra from New Zealand market

-April 12, 2005

Pfizer has voluntarily withdrawn Bextra from the New Zealand market. Last week, the U.S. Food and Drug Administration asked Pfizer to remove Bextra from the market after deciding the risks of using Bextra outweigh its benefits, though Pfizer disagreed with the agency's request. Bextra is linked to increased risks of heart attacks and strokes, like all COX-2 inhibitors, in addition to a potentially deadly skin disease called Stevens Johnson syndrome.

For more information on bextra, please contact us.

More Recent Defective Drug News

Contact a News Recall Lawyer